Identifying cell lines across pan-cancer to be used in preclinical research as a proxy for patient tumor samples.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
07 Sep 2024
07 Sep 2024
Historique:
received:
05
01
2023
accepted:
30
08
2024
medline:
8
9
2024
pubmed:
8
9
2024
entrez:
7
9
2024
Statut:
epublish
Résumé
In pre-clinical trials of anti-cancer drugs, cell lines are utilized as a model for patient tumor samples to understand the response of drugs. However, in vitro culture of cell lines, in general, alters the biology of the cell lines and likely gives rise to systematic differences from the tumor samples' genomic profiles; hence the drug response of cell lines may deviate from actual patients' drug response. In this study, we computed a similarity score for the selection of cell lines depicting the close and far resemblance to patient tumor samples in twenty-two different cancer types at genetic, genomic, and epigenetic levels integrating multi-omics datasets. We also considered the presence of immune cells in tumor samples and cancer-related biological pathways in this score which aids personalized medicine research in cancer. We showed that based on these similarity scores, cell lines were able to recapitulate the drug response of patient tumor samples for several FDA-approved cancer drugs in multiple cancer types. Based on these scores, several of the high-rank cell lines were shown to have a close likeness to the corresponding tumor type in previously reported in vitro experiments.
Identifiants
pubmed: 39244634
doi: 10.1038/s42003-024-06812-3
pii: 10.1038/s42003-024-06812-3
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1101Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
ID : R35GM133657
Informations de copyright
© 2024. The Author(s).
Références
Ben-David, U. et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560, 325–330 (2018).
pubmed: 30089904
pmcid: 6522222
doi: 10.1038/s41586-018-0409-3
Gillet, J.-P., Varma, S. & Gottesman, M. M. The clinical relevance of cancer cell lines. J. Natl Cancer Inst. 105, 452–458 (2013).
pubmed: 23434901
pmcid: 3691946
doi: 10.1093/jnci/djt007
Tomczak, K., Czerwińska, P. & Wiznerowicz, M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. 19, A68–A77 (2015).
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
pubmed: 22460905
pmcid: 3320027
doi: 10.1038/nature11003
Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955–D961 (2013).
pubmed: 23180760
doi: 10.1093/nar/gks1111
Liu, K. et al. Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data. Nat. Commun. 10, 1–12 (2019).
Sandberg, R. & Ernberg, I. Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc. Natl Acad. Sci. USA 102, 2052 (2005).
pubmed: 15671165
pmcid: 548538
doi: 10.1073/pnas.0408105102
Warren, A. et al. Global computational alignment of tumor and cell line transcriptional profiles. Nat. Commun. https://doi.org/10.1038/s41467-020-20294-x (2021).
Decamps, C. et al. Guidelines for cell-type heterogeneity quantification based on a comparative analysis of reference-free DNA methylation deconvolution software. BMC Bioinformatics 21, 16 (2020).
Grün, D. Revealing dynamics of gene expression variability in cell state space, Nat. Methods https://doi.org/10.1038/s41592-019-0632-3 (2019).
Gun, S. Y., Lee, S. W. L., Sieow, J. L. & Wong, S. C. Targeting immune cells for cancer therapy. Redox Biol. 25, 101174 (2019).
pubmed: 30917934
pmcid: 6859550
doi: 10.1016/j.redox.2019.101174
Neal, J. T. et al. Organoid modeling of the tumor immune microenvironment. Cell 175, 1972–1988 (2018).
Tsou, P., Katayama, H., Ostrin, E. J. & Hanash, S. M. The emerging role of B cells in tumor immunity. Cancer Res. 76, 5597–5601 (2016).
pubmed: 27634765
doi: 10.1158/0008-5472.CAN-16-0431
Kao, J. et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 4, e6146 (2009).
pubmed: 19582160
pmcid: 2702084
doi: 10.1371/journal.pone.0006146
Neve, R. M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515–527 (2006).
pubmed: 17157791
pmcid: 2730521
doi: 10.1016/j.ccr.2006.10.008
Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nat. Med. 10, 789–799 (2004).
pubmed: 15286780
doi: 10.1038/nm1087
Mattes, M. J. Apoptosis assays with lymphoma cell lines: problems and pitfalls. Br. J. Cancer 96, 928–936 (2007).
pubmed: 17342089
pmcid: 2360094
doi: 10.1038/sj.bjc.6603663
Feng, H. et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1 and ICAM1 Leading to a Blockade of Tumor Cell Intravasation. Cancer Cell 18, 353–366 (2010).
pubmed: 20951945
pmcid: 3003429
doi: 10.1016/j.ccr.2010.09.009
Bose, B. & Bozdag, S. CTDPathSim: cell line-tumor deconvoluted pathway-based similarity in the context of precision medicine in cancer. In Proc. 11th ACM International Conference on Bioinformatics, Computational Biology and Health Informatics, in BCB ’20 1–10 (Association for Computing Machinery, 2020).
Cheng, L. et al. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma. BMC Med. Genom. 12, 23 (2019).
doi: 10.1186/s12920-018-0456-5
Sun, Y. & Liu, Q. Deciphering the correlation between breast tumor samples and cell lines by integrating copy number changes and gene expression profiles. BioMed. Res. Int. 2015, 901303 (2015).
pubmed: 26273658
pmcid: 4529967
doi: 10.1155/2015/901303
Wu, Q. et al. Cancer-associated adipocytes: key players in breast cancer progression. J. Hematol. Oncol. 12, 95 (2019).
pubmed: 31500658
pmcid: 6734503
doi: 10.1186/s13045-019-0778-6
Mukherjee, O., Rakshit, S., Shanmugam, G. & Sarkar, K. Role of chemotherapeutic drugs in immunomodulation of cancer. Curr. Res Immunol. 4, 100068 (2023).
pubmed: 37692091
pmcid: 10491645
doi: 10.1016/j.crimmu.2023.100068
Hughes, E. et al. T‐cell modulation by cyclophosphamide for tumour therapy. Immunology 154, 62–68 (2018).
pubmed: 29460448
pmcid: 5904691
doi: 10.1111/imm.12913
Verma, R. et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 18, 10 (2016).
pubmed: 26810608
pmcid: 4727393
doi: 10.1186/s13058-015-0669-x
Kubota, Y., Ohji, H., Itoh, K., Sasagawa, I. & Nakada, T. Changes in cellular immunity during chemotherapy for testicular cancer. Int. J. Urol. 8, 604–608 (2001).
pubmed: 11903686
doi: 10.1046/j.1442-2042.2001.00392.x
Godoy-Ortiz, A. et al. Deciphering HER2 breast cancer disease: biological and clinical implications. Front. Oncol. https://doi.org/10.3389/fonc.2019.01124 (2019).
Tsoi, J. et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell 33, 890–904.e5 (2018).
pubmed: 29657129
pmcid: 5953834
doi: 10.1016/j.ccell.2018.03.017
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
pubmed: 10647931
doi: 10.1016/S0092-8674(00)81683-9
Sever, R. & Brugge, J. S. Signal transduction in cancer. Cold Spring Harb. Perspect. Med. https://doi.org/10.1101/cshperspect.a006098 (2015).
Gonzalez, H., Hagerling, C. & Werb, Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267–1284 (2018).
pubmed: 30275043
pmcid: 6169832
doi: 10.1101/gad.314617.118
Vishnoi, K., Viswakarma, N., Rana, A. & Rana, B. Transcription factors in cancer development and therapy. Cancers 12, 2296 (2020).
pubmed: 32824207
pmcid: 7464564
doi: 10.3390/cancers12082296
Hernandez, L. et al. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol. Oncol. 142, 332–340 (2016).
pubmed: 27235858
pmcid: 4961516
doi: 10.1016/j.ygyno.2016.05.028
Del Vecchio, C. A. et al. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene https://doi.org/10.1038/onc.2012.280 (2013).
Donnou, S. et al. Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv. Hematol. 2012, 701704 (2012).
pubmed: 22400032
pmcid: 3287022
doi: 10.1155/2012/701704
Chen, Z. et al. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo. J. Exp. Clin. Cancer Res. 37, 190 (2018).
pubmed: 30103789
pmcid: 6090784
doi: 10.1186/s13046-018-0863-7
Eberth, S. et al. Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma. BMC Cancer 10, 517 (2010).
pubmed: 20920234
pmcid: 2955612
doi: 10.1186/1471-2407-10-517
Kuroiwa, Y. et al. Proliferative classification of intracranially injected HER2-positive breast cancer cell lines. Cancers https://doi.org/10.3390/cancers12071811 (2020).
Carlisle, S. M. & Hein, D. W. Retrospective analysis of estrogen receptor 1 and N‑acetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines. Int. J. Oncol. 53, 694–702 (2018).
pubmed: 29901116
pmcid: 6017241
Kobayashi, M. et al. Functional analysis of novel candidate regulators of insulin secretion in the MIN6 mouse pancreatic β cell line. PLoS ONE 11, e0151927 (2016).
pubmed: 26986842
pmcid: 4795703
doi: 10.1371/journal.pone.0151927
Colaprico, A. et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71 (2016).
pubmed: 26704973
doi: 10.1093/nar/gkv1507
Zhang, J. CNTools: convert segment data into a region by sample matrix to allow for other high level computational analyses. In: R Package Version 1.40.0 https://bioconductor.org/packages/release/bioc/html/CNTools.html (2019).
Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
pubmed: 30371878
doi: 10.1093/nar/gky1015
Wang, Y., Franks, J. M., Whitfield, M. L. & Cheng, C. BioMethyl: an R package for biological interpretation of DNA methylation data. Bioinformatics 35, 3635–3641 (2019).
pubmed: 30799505
pmcid: 6761945
doi: 10.1093/bioinformatics/btz137
Xu, Z., Niu, L., Li, L. & Taylor, J. A. ENmix: a novel background correction method for Illumina HumanMethylation450 BeadChip. Nucleic Acids Res. 44, e20 (2016).
pubmed: 26384415
doi: 10.1093/nar/gkv907
Jaffe, A. E. FlowSorted.Blood.450k: Illumina HumanMethylation data on sorted blood cell populations. In: Bioconductor R Package Version https://bioconductor.org/packages/release/data/experiment/html/FlowSorted.Blood.450k.html (2020).
Hansen, K. D. et al. minfi: Analyze Illumina Infinium DNA methylation arrays. In: Bioconductor Version: Release (3.11) https://doi.org/10.18129/B9.bioc.minfi (2020).
Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012).
pubmed: 22460902
pmcid: 3349233
doi: 10.1038/nature11005
Onuchic, V. et al. Epigenomic deconvolution of breast tumors reveals metabolic coupling between constituent cell types. Cell Rep. 17, 2075–2086 (2016).
pubmed: 27851969
pmcid: 5115176
doi: 10.1016/j.celrep.2016.10.057
Koestler, D. C. et al. Blood-based profiles of DNA methylation predict the underlying distribution of cell types: a validation analysis. Epigenetics 8, 816–826 (2013).
pubmed: 23903776
pmcid: 3883785
doi: 10.4161/epi.25430
Titus, A. J., Gallimore, R. M., Salas, L. A. & Christensen, B. C. Cell-type deconvolution from DNA methylation: a review of recent applications. Hum. Mol. Genet. 26, R216–R224 (2017).
pubmed: 28977446
pmcid: 5886462
doi: 10.1093/hmg/ddx275
Maunakea, A. K. et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466, 253–257 (2010).
pubmed: 20613842
pmcid: 3998662
doi: 10.1038/nature09165
Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 48, D498–D503 (2020).
pubmed: 31691815
Ulgen, E. egeulgen/pathfindR). R https://github.com/egeulgen/pathfindR (2020).
Du, P. et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinform. 11, 587 (2010).
doi: 10.1186/1471-2105-11-587
Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
pubmed: 21527027
pmcid: 3218867
doi: 10.1186/gb-2011-12-4-r41
Reich, M., Liefeld, T., Tamayo, P. & Mesirov, J. GenePattern 2.0. Nat. Genet. 38, 500–501 (2006).
pubmed: 16642009
doi: 10.1038/ng0506-500
Tukey’s range test, Wikipedia (2020). Accessed: Jan. 09, 2021. [Online]. Available: https://en.wikipedia.org/w/index.php?title=Tukey%27s_range_test&oldid=979274615
Warren, A. et al. Global computational alignment of tumor and cell line transcriptional profiles. Nat Commun 12, 22 (2021).
Serdar, B. & Bose, B. CTDPathSim2.0 Dataset [DS/OL]. V2. Science Data Bank https://doi.org/10.57760/sciencedb.01713 (2022).